Citations

Association of Outpatient Follow-up with 30-day Readmission after Epilepsy or Seizure Discharge in Medicare Beneficiaries Aged 65 and Older Blank LJ, Van Hyfte G, Agarwal P, Mazumdar M, Jette J. Neurology . 2025;104(10):e213638. Background and Objectives: Older adults are expected to have higher readmission rates after seizure-related hospitalization. We sought to define the 30-day readmission rate for older adults after seizure hospitalization and to examine whether occurrence, timing, or specialization of follow-up with primary or neuro-related care is associated with lower readmission risk. Methods: This is a retrospective cohort study using 2016–2019 Medicare claims data, including adults aged older than 65 years hospitalized with a primary diagnosis of seizure/epilepsy. The primary outcome was readmission within 30 days. Exposure of interest was presence or absence of follow-up and specialty of the follow-up provider. Beneficiaries were followed from 90 days before admission to 30 days after discharge. We defined variables a priori based on literature/clinical judgment and used a least absolute shrinkage and selection operator (LASSO) method to determine factors that were contributing to the data's variance for inclusion in the final model. Results: Of 80,620 beneficiaries with admissions for seizure/epilepsy, 17.72% were readmitted within 30 days. Overall, 20.6% saw only primary care, 2.5% neurology only, 0.3% neurosurgery only, and 0.1% epilepsy only, and 5.4% had a combination of visits. Readmission rates differed by follow-up visit status: 22% readmission rate for those with no follow-up and only 6% with any health care visit. Among those with a visit, the readmission rates by specialty were as follows: 8% for primary care alone, 5% for neurology alone, 16% for neurosurgery alone, 1% for epileptology alone, and 2% for those who had seen a combination of these specialties. In our LASSO-selected multivariable model, outpatient follow-up was associated with lower odds of readmission: early (days 1–15) primary care visit (adjusted odds ratio [aOR] 0.49; 95% CI 0.45–0.52, p < .001); early neurology visit (aOR 0.39; 95% CI 0.33–0.46, p < .001); and later (days 16–30) neurosurgery visit (aOR 0.42; 95% CI 0.27–0.67, p < .001), later neurology visit (aOR 0.16; 95% CI 0.13–0.21, p < .001), or later primary care visit (aOR 0.16; 95% CI 0.14–0.17, p < .001), all associated with reduced odds of readmission. Discussion: We found high rates of readmission in older adults. Outpatient follow-up was associated with reduced odds of readmission. These findings reinforce the importance of discharge planning and suggest that ensuring outpatient follow-up with either primary care or neurology may be an easy intervention to reduce readmissions.

AbstractFatiguing inspiratory work has been shown to evoke a sympathetically mediated reflex that has systemic cardiovascular consequences, including increases in heart rate and blood pressure and a decrease in resting limb vascular conductance. Moreover, the response to this reflex appears to be attenuated in females compared with males. It remains to be seen whether this respiratory muscle metaboreflex also exerts an effect on cerebral blood flow. Cerebral blood flow is tightly regulated to maintain homeostasis and critical function. Therefore, it stands to reason that cerebrovascular haemodynamics would not be compromised through this respiratory muscle metaboreflex. We hypothesized that fatiguing inspiratory work would reduce resting limb conductance, but cerebral blood flow would be minimally impaired. Females (34 ± 10 years old, n = 12) and males (31 ± 8 years old, n = 12) performed a 5 min, high‐intensity bout of inspiratory pressure threshold loading (IPTL) designed to evoke the respiratory muscle metaboreflex. In response to IPTL, mean arterial pressure increased in both males and females (p < 0.001), and limb vascular conductance decreased to a greater degree in males than in females (p = 0.005). The cerebrovascular conductance index was higher in females (p = 0.007) but not affected by IPTL (p = 0.417). Our findings suggest that cerebral blood flow is spared from the redistribution of blood flow in response to fatiguing inspiratory work and that this protection is true in both males and females.

Importance Little research has been done on post-COVID symptoms at 24 months postinfection and on the association these may have on health-related quality of life (HRQOL). Objective We assessed the prevalence and severity of post-COVID symptoms and quantified EuroQol 5 Dimension 5 Level (EQ-5D-5L), self-perceived health question (EuroQol Visual Analogue Scale (EQ-VAS)) and health utility scores (HUS) up to 24 months follow-up. Design The longitudinal multiple cohort CORona Follow-Up (CORFU) study combines seven COVID-19 patient cohorts and a survey among the general public. The participants received questionnaires on several time points. Participants were stratified by: without a known SARS-CoV-2 infection (control group), proven SARS-CoV-2 infection but non-hospitalised, proven SARS-CoV-2 infection hospitalised to the ward, and proven SARS-CoV-2 infection hospitalised to the intensive care unit (ICU). Setting In this study, data of seven COVID-19 patient cohorts and a survey among the general public are included. Participants Former COVID-19 patients and controls participated in this cohort study. Main outcomes and measures Former COVID-19 patients and non-COVID-19 controls were sent questionnaires on symptoms associated with post-COVID condition. The CORFU questionnaire included 14 symptom questions on post-COVID condition using a five-level Likert-scale format. Furthermore, HRQOL was quantified using the EuroQol EQ-5D-5L questionnaire: EQ-VAS and the EQ-5D-5L utility score. The EQ-5D-5L questionnaire includes five domains that are scored on a five-point Likert scale: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Results A total of 901 participants (and 434 controls) responded at 24 months follow-up. In all former COVID-19 patients, the presence of post-COVID condition at 24 months was observed in 62 (42.5%, 95% CI 34.3% to 50.9%) of the non-hospitalised patients, 333 (65.0%, 95% CI 60.7% to 69.2%) of the hospitalised ward patients and 156 (63.2%, 95% CI 56.8% to 69.2%) of the ICU patients, respectively (p<0.001). The most common symptoms included fatigue, sleep problems, muscle weakness/pain and breathing issues, with hospitalised participants reporting most often having symptoms. Multiple post-COVID symptoms were significantly associated with EQ-5D-5L measures. The mean and SD of the EQ-VAS were 71.6 (17.9), 70.0 (17.3) and 71.4 (17.5) for non-hospitalised, ward and ICU participants, respectively, and 75.6 (17.7) for the controls (p<0.001). The HUS resulted in 0.81 (0.20), 0.77 (0.19) and 0.79 (0.22) for non-hospitalised, hospitalised ward and ICU participants, respectively, and 0.84 (0.19) for the control group (CG) (p<0.001). Conclusions Many former COVID-19 patients experience post-COVID symptoms at 24 months follow-up, with the highest prevalence in hospitalised participants. Also, former patients reported a lower HRQOL. Trial registration number The CORFU study was registered at clinicaltrials.gov (registration number NCT05240742).

The aortic pulsatility index (API) (systolic blood pressure-diastolic blood pressure/pulmonary capillary wedge pressure [PCWP]) integrates ventricular output with left ventricular (LV) filling pressures. It offers a surrogate for ventricular-arterial coupling and is associated with the need for advanced therapies and outcomes in decompensated heart failure. However, its use in patients in cardiogenic shock requiring temporary mechanical circulatory support (tMCS) is limited and requires invasive measurement of PCWP. This case series evaluates the concept of echo-API as a noninvasive tool to estimate API using Doppler echocardiography, and its feasibility in patients with cardiogenic shock on tMCS.

Purpose: Model interpretability is a critical requirement for deploying artificial intelligence (AI) applications in clinical speech settings, yet existing evaluation methods often overlook this aspect. The complex nature of speech features and the opaque decision-making processes of AI models underscore the need for a tailored framework to assess interpretability in speech-based clinical AI systems. This article proposes an initial framework composed of eight key factors to consider when evaluating the interpretability of clinical speech AI models. These factors are categorized into two groups: functional factors and clinician-centered factors. The functional factors, which can be assessed independently without user involvement, include faithfulness and computational efficiency. The clinician-centered factors include four established ones from existing literature (cognitive load, human–AI task performance, mental model, and user trust) and two new factors tailored to the unique demands of clinical speech applications: clinical understandability and decision relevance. We further suggest evaluation methods for each of the identified factors and propose modifying existing instruments such as the System Usability Scale and the Healthcare Systems Usability Scale to evaluate the two newly introduced factors. Conclusions: Our identified factors form an initial framework for evaluating the interpretability of speech-based clinical AI systems, supporting the effective integration of AI into clinical workflows. Future works include conducting an evaluation experiment using the proposed framework and refining it further based on the findings from the experiment.

Background Pseudohallucinations (PHs), defined as perceptual experiences recognized by the individual as unreal, have historically been distinguished from “true” hallucinations. However, their conceptual validity and clinical utility remain debated, with definitions and applications varying widely. Methods A narrative review of historical and contemporary literature on PHs was conducted. Articles were identified through PubMed using the terms “pseudohallucination,” “hallucination,” “dissociation,” and “trauma,” and through reviewing reference lists of key publications. Results Historical accounts emphasized features such as insight and localization, but empirical findings challenge these distinctions and demonstrate significant overlap with hallucinations and intrusive imagery across diagnoses. PHs are observed in psychotic, trauma-related, and personality disorders, suggesting they may reflect a spectrum of perceptual experiences rather than a discrete entity. Conclusions Moving beyond binary classifications and exploring the use of specifiers to describe hallucinations may offer a more nuanced framework for understanding these experiences across diagnostic categories. Rather than seeking rigid distinctions, this approach encourages descriptions that reflect individual phenomenology and context. Such a shift may help reduce stigma, foster more compassionate clinical engagement, and preserve the perceived relevance of the PH concept while aligning it with contemporary dimensional models of psychopathology.

ABSTRACT Levator ani syndrome (LAS) explains up to 7.4% of anorectal pain cases. Classic symptoms include rectal pain or pressure with sitting. We present 2 patients, ages 32 and 25 years, presenting initially with “diarrhea” and perianal hyperhidrosis. History revealed rectal discomfort, tenesmus, urgency, and sensation of incomplete evacuation. Puborectalis tenderness was present on digital rectal examination. Therapies were tailored to each patient, including pelvic floor physical therapy with biofeedback, bowel regulation, rectal diazepam, and ileostomy. These presentations offer insights into potential pathophysiological mechanisms in LAS and highlight the importance of considering LAS in non-pain presentations.

ABSTRACT Background The available risk prediction models are inadequate to identify a true low‐risk patient for developing new‐onset atrial fibrillation (AF) after typical atrial flutter (AFL) ablation. We aimed to determine whether adding markers of atrial myopathy to HATCH score ( h ypertension, a ge ≥75 years, t ransient ischemic attack/stroke, c hronic obstructive pulmonary disease, and h eart failure) can improve prediction of new‐onset AF after ablation of typical AFL. Methods The study included 208 consecutive patients who underwent successful ablation of typical AFL at Minneapolis VA Medical Center and University of Minnesota Medical Center. Patients with history of AF prior to ablation were excluded. Results Among the 208 patients, 76 (36.5%) developed new‐onset AF post AFL ablation. Mean follow‐up duration was 62 ± 31.8 months. HATCH score was not associated with new‐onset AF. When adding atrial myopathy (presence of at least one of the following: PTFV 1 > 5000 µV*ms, interatrial block determined by biphasic inferior p wave with duration >120 ms, left atrium (LA) diameter ≥44 mm, or LA index ≥3 cm/m 2 ) to HATCH score (HATCH‐A 2 ), the combination was independently associated with new‐onset AF. The AF incidence between HATCH‐A 2 score of 0–1 and ≥2 were 6.7% and 40.5%, respectively (Odds ratio 9.04, 95% confidence interval: 2.05–39.81, p = 0.004). Particularly, when HATCH‐A 2 score was 0, none of the patients developed AF. Conclusions Adding atrial myopathy to HATCH score improved predictability and could be used to delineate a true low‐risk patient of new‐onset AF after typical AFL ablation.

Objectives To compare survival and oncological outcomes of cisplatin‐ineligible patients (Cis‐I) and cisplatin‐eligible (Cis‐E) patients with muscle‐invasive bladder cancer (MIBC) undergoing immediate radical cystectomy (IRC), as IRC is currently considered the standard‐of‐care for Cis‐I patients with MIBC. Patients and Methods Data from patients with clinical (c)T2–4cN0–1M0 MIBC undergoing IRC, between 2006 and 2021, were retrospectively analysed from four tertiary care centres in the United States. Overall, recurrence‐free and event‐free survival were described using the Kaplan–Meier method and tested using the log‐rank test. For context, we compared survival outcomes against those in Cis‐E patients with MIBC undergoing IRC from the Southwest Oncology Group (SWOG)‐8710 trial. Results Overall, 379 Cis‐I and 125 Cis‐E patients with cT2–4cN0–1M0 MIBC who underwent IRC were included. Cis‐I patients included 44.8% cT3/4 vs 60% cT3/4 in the Cis‐E group. Overall, 83.3% of Cis‐I and 79.2% of Cis‐E patients died during follow‐up. The median event‐free and overall survival were 12.1 and 14.5 months for the Cis‐I group and 28.8 and 60.1 months for the Cis‐E group ( P < 0.001). [Correction added on 10 October 2025, after first online publication: The preceding sentence has been revised in this version.] Limitations include retrospective comparison of contemporary multi‐institutional data with that of a randomised control trial. Conclusions The Cis‐I patients with MIBC undergoing IRC fared poorly, with a median overall survival of 14.5 (95% confidence interval 11.1–17.9) months, mostly due to non‐cancer‐related deaths. These results provide a benchmark for clinical trials exploring novel agents or alternative chemotherapy regimens in Cis‐I patients with MIBC.